

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-7. (Canceled)

1/ 8. (Currently Amended) A method of inhibiting angiogenesis in pathological conditions where increased angiogenesis and coincidental vascular perfusion are clinically detrimental, comprising the steps of: producing an AT₄ receptor ligand, having a structure selected from the group consisting of NH₃⁺-norleucine-tyrosine-isoleucine-histidine-COO⁻ (SEQ ID NO: 4), and norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-CONH₂ (SEQ ID NO: 1); and administering the AT₄ receptor ligand.

2/ 3/ 9. (Allowed) The method of inhibiting angiogenesis according to claim 8/ or claim 29, further comprising the delivery of the AT₄ receptor ligand locally.

2/ 4/ 10. (Allowed) The method of inhibiting angiogenesis according to claim 8/ or claim 29, further comprising the delivery of the AT₄ receptor ligand intravascularly.

2/ 5/ 11. (Allowed) The method of inhibiting angiogenesis according to claim 8/ or claim 29, further comprising the delivery of the AT₄ receptor ligand intramuscularly.

2/ 6/ 12. (Allowed) The method of inhibiting angiogenesis according to claim 8/ or claim 29, further comprising the delivery of the AT₄ receptor ligand intraperitoneally.

2 7 13. (Allowed) The method of inhibiting angiogenesis according to claim 8 or claim 29, further comprising the delivery of the AT₄ receptor ligand subcutaneously.

2 8 14. (Allowed) The method of inhibiting angiogenesis according to claim 8 or claim 29, further comprising the delivery of the AT₄ receptor ligand orally.

9 15. (Currently Amended) A method of inhibiting the growth and metastasis of solid tumors, comprising the steps of: producing an AT₄ receptor ligand, having a structure selected from the group consisting of: NH₃⁺-norleucine-tyrosine-isoleucine-histidine-COO⁻ (SEQ ID NO: 4), and norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-CONH₂ (SEQ ID NO: 1); and administering the AT₄ receptor ligand.

11 16. (Allowed) The method of inhibiting the growth and metastasis of solid tumors according to claim 15 or claim 30, further comprising delivery of the AT₄ receptor ligand locally.

12 17. (Allowed) The method of inhibiting the growth and metastasis of solid tumors according to claim 15 or claim 30, further comprising the delivery of the AT₄ receptor ligand intravascularly.

13 18. (Allowed) The method of inhibiting the growth and metastasis of solid tumors according to claim 15 or claim 30, further comprising the delivery of the AT₄ receptor ligand intramuscularly.

14 19. (Allowed) The method of inhibiting the growth and metastasis of solid tumors according to claim 15 or claim 30, further comprising the delivery of the AT₄ receptor ligand intraperitoneally.

¹⁵
~~20~~. (Allowed) The method of inhibiting the growth and metastasis of solid tumors according to claim ~~15~~ or claim ~~30~~, further comprising the step of applying the AT₄ receptor ligand subcutaneously. ⁹ ~~10~~

¹⁶
~~21~~. (Allowed) The method of inhibiting the growth and metastasis of solid tumors according to claim ~~15~~ or claim ~~30~~, further comprising the step of applying the AT₄ receptor ligand orally. ⁹ ~~10~~

¹⁷
~~22~~. (Currently Amended) A method of inhibiting the growth and metastasis of breast cancer, comprising the steps of: producing an AT₄ receptor ligand, having a structure selected from the group consisting of: NH₃⁺-norleucine-tyrosine-isoleucine-histidine-COO⁻ (SEQ ID NO: 4), and norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-CONH₂ (SEQ ID NO: 1); and administering the AT₄ receptor ligand.

¹⁹~~23~~. (Allowed) The method of inhibiting the growth and metastasis of breast cancer according to claim ~~22~~ or claim ~~31~~, further comprising the delivery of the AT₄ receptor ligand locally to the tumor. ¹⁷ ~~18~~

²⁰~~24~~. (Allowed) The method of inhibiting the growth and metastasis of breast cancer according to claim ~~22~~ or claim ~~31~~, further comprising the delivery of the AT₄ receptor ligand intravascularly. ¹⁷ ~~18~~

²¹~~25~~. (Allowed) The method of inhibiting the growth and metastasis of breast cancer according to claim ~~22~~ or claim ~~31~~, further comprising the delivery of the AT₄ receptor ligand intramuscularly. ¹⁷ ~~18~~

²²~~26~~. (Allowed) The method of inhibiting the growth and metastasis of breast cancer according to claim ~~22~~ or claim ~~31~~, further comprising the delivery of the AT₄ receptor ligand intraperitoneally. ¹⁷ ~~18~~

23/21. (Allowed) The method of inhibiting the growth and metastasis of breast cancer according to claim 22 or claim 31, further comprising the delivery of the AT₄ receptor ligand subcutaneously. 17 18

24/28. (Allowed) The method of inhibiting the growth and metastasis of breast cancer according to claim 22 or claim 31, further comprising the delivery of the AT₄ receptor ligand orally.

2/29. (Currently Amended) A method of inhibiting angiogenesis in pathological conditions where increased angiogenesis and coincidental vascular perfusion are clinically detrimental, comprising the steps of: producing an AT₄ receptor ligand having a structure of: norleucine-tyrosine-leucine-Ψ-(CH₂-NH₂)³⁻⁴-histidine-proline-phenylalanine-COO⁻ (SEQ ID NO: 3); and administering the AT₄ receptor ligand.

10/30. (Currently Amended) A method of inhibiting the growth and metastasis of solid tumors, comprising the steps of: producing an AT₄ receptor ligand having a structure of: norleucine-tyrosine-leucine-Ψ-(CH₂-NH₂)³⁻⁴-histidine-proline-phenylalanine-COO⁻ (SEQ ID NO: 3); and administering the AT₄ receptor ligand.

18/31. (Currently Amended) A method of inhibiting the growth and metastasis of breast cancer, comprising the steps of: producing an AT₄ receptor ligand having a structure of: norleucine-tyrosine-leucine-Ψ-(CH₂-NH₂)³⁻⁴-histidine-proline-phenylalanine-COO⁻ (SEQ ID NO: 3); and administering the AT₄ receptor ligand.